The Food and Drug Administration (FDA) in the United States has launched an attack on the biotech company Amylin about its testing on the side effects of two of its diabetes drugs.
The regulator has accused Amylin of withholding key data from patient testing regarding the cardiac side effects of the diabetes drugs Byetta and Bydureon. The FDA claimed that the company had offered just the title of a study and not its contents, and when asked for the data on Bydureo, it gave them an updated version of previous Byetta documentation.
Mary Parks, a division director of the FDA who oversees diabetes treatments, said the case “has been long and complicated…in part due to Amylin’s withholding of information on Byetta that FDA deemed important to its evaluation of the safety and effectiveness of Bydureon.”
Amylin is being considered for take-over by a range of international competitors, such as AstraZenecan, Roche, Bristol-Myers Squibb, Pfizer, Sanofi and Merck, who are looking to increase their market share in diabetes drugs, especially with many patents currently due to expire.
Amylin commented that “it was “committed to being transparent with regulatory agencies, the patients and physicians who put their trust in our products and our investor community. Our interactions with regulatory agencies have bee, and will continue to be, forthright and timely”.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…